Business Context and Reporting Period
This Form 8-K Current Report from Matinas Biopharma Holdings, Inc. covers events occurring on October 7, 2016, and the Annual Meeting of Stockholders held on October 13, 2016. The filing details executive leadership changes and the results of shareholder votes on director elections, auditor ratification, and corporate governance amendments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and personnel matters rather than financial performance data.
Material Changes
Executive Appointment
- Raphael J. Mannino was promoted from Chief Technology Officer to Chief Scientific Officer effective October 7, 2016.
- His base salary was increased to $230,000 per year, effective October 1, 2016.
- All other terms of his employment agreement remain unchanged.
Shareholder Vote Results
At the Annual Meeting on October 13, 2016, stockholders voted on three proposals:
- Election of Directors: Herbert Conrad, Roelof Rongen, Stefano Ferrari, Adam Stern, and James Scibetta were elected to the Board of Directors. Each received 30,799,993 votes "For," 7,200 "Withheld," and 11,977,987 "Non-Votes."
- Auditor Ratification: Stockholders approved the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016. Votes: 42,281,574 "For," 503,606 "Against," and 0 "Abstain."
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation granting the Board discretionary authority to effect a reverse stock split. Votes: 41,790,105 "For," 995,074 "Against," and 1 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on future operations, or a discussion of risks and contingencies beyond the standard disclosure of the reverse stock split authority.
Investor Verification Checklist
- Verify the impact of the reverse stock split authorization on share price and liquidity, noting the Board now holds discretionary authority to execute it.
- Review the employment agreement for Raphael J. Mannino (Exhibit 10.1 to the September 1, 2015, 8-K) to confirm the full scope of compensation and terms.
- Confirm the composition of the Board of Directors for the 2016-2017 term based on the election results.
- Check subsequent filings to determine if the Board exercises the authority to implement a reverse stock split.